Hepatotoxicity associated with ribociclib among breast cancer patients.

CDK4/6 inhibitors combined with endocrine therapy (ET) have become standard treatment for endocrine receptor (ER) positive, Her-2 negative metastatic breast cancer. Three agents, palbociclib, riboc...